It is well known that oxidative stresses induce the production of amyloid β (Aβ) in the brain, lens, and retina, leading to age-related diseases. In the present study, we investigated the effects of ferulic acid on the Aβ levels in H2O2-stimulated human lens epithelial (HLE) SRA 01/04 cells. Three types of Aβ peptides (Aβ1-40, Aβ1-42, and Aβ1-43) were measured by ELISA, and the levels of mRNA for the expressed proteins related to Aβ production (APP, BACE1, and PS proteins) and degradation (ADAM10, NEP, and ECE1 proteins) were determined by quantitative real-time RT-PCR. H2O2 stimulation augmented gene expression of the proteins related to Aβ production, resulting in the production of three types of Aβ peptides. Treatment with 0.1 μM ferulic acid attenuated the augmentations of gene expression and production of the proteins related to the secretion of three types of Aβ peptides in the H2O2-stimulated HLE cells. These results provided evidence of antioxidative functions of ferulic acid for lens epithelial cells.
We attempted to design a combination ointment containing solid tranilast nanoparticles and dissolved sericin as a wound-healing drug (TS-combination ointment), and evaluated its usefulness as therapy for wound-healing deficits in streptozotocin-induced diabetic rat (STZ rat) using kinetic analyses as an index. Solid tranilast nanoparticles were prepared by bead mill methods with low-substituted methylcellulose; the mean particle size of the tranilast nanoparticles was 70 nm. The ointment was designed to contain the tranilast nanoparticles plus sericin powder and/or Carbopol ® 934. Skin wound healing in STZ rats begins significantly later than in normal rats. Although the skin wound healing rate in STZ rats treated with an ointment containing tranilast nanoparticles was lower than in STZ rats treated with vehicle, the ointment was effective in reducing redness. An ointment containing sericin enhanced the skin-healing rate, but the preventive effect on redness was weak. On the other hand, the combination of tranilast and sericin increased both the skin healing rate and reduction in redness. In conclusion, we have adapted kinetic analyses to skin wound healing in rats, and found these analyses to be useful as an index of wound healing ability by a wound-healing drug. In addition, we show that treatment with the TS-combination ointment enhances the skin wound healing rate and reduces redness. These findings provide information significant to the search for new wound-healing therapies and for the design of wound-healing drugs.Key words tranilast; sericin; skin wound healing; redness; diabetes mellitus Diabetes mellitus is characterized by a dysfunction in glucose metabolism associated with the subsequent negative effects on lipid and protein metabolism. The most common dermatological complications in diabetic patients are woundhealing deficits.1) Wound healing is a preprogrammed process consisting of four continuous phases: (1) bleeding controlled by hemostasis, (2) inflammatory response, (3) cellular and collagen proliferation, and (4) remodeling.2-5) Following injury, the inflammatory response takes place from 0-3 d, and cellular proliferation occurs at 3-12 d. During the inflammatory response, monocytes and macrophages release various cytokines, and the number of fibroblasts increases. The fibroblasts induce collagen synthesis, and collagen replenishes the skin deficit area. Thus, collagen synthesis via cytokine release (inflammatory response) is important in the process of skin wound healing. On the other hand, wound healing via abnormal collagen synthesis and formulation during a prolonged inflammatory response is the cause of redness and keloid formation in the skin. A decrease in collagen synthesis results in delayed skin healing.
The ophthalmic application is the main route for the therapy of glaucoma, and is well-accepted by glaucoma patients. Therefore, it is important to measure the drug behavior in lacrimal fluid after instillation of eye drops. In this study, we used ophthalmic formulation (eye drops) containing timolol maleate (TM), in anti-glaucoma eye drops, and attempted to measure the drug behavior after instillation of TM eye drops. First, we collected the lacrimal fluid (5 μL) every 10 time after instillation using micropipette, and measured by the HPLC method. The TM concentration in lacrimal fluid was 21.2 μg/mL at 5 min after the instillation, and the TM was remained for 30 min after the instillation. Next, we collected the lacrimal fluid via the dialysis prove, and measured by the HPLC method. The retention of TM in lacrimal fluid was observed for 45 min after the instillation, and the measurement accuracy was enhanced by system with an automatic injection of TM solution via dialysis prove (microdialysis-HPLC method). In addition, the measurement accuracy increased more by using a capillary liquid chromatography (CLC) instead of an HPLC (microdialysis-CLC method), and the retention time of TM in lacrimal fluid was extended to 75 min after the instillation. In conclusion, we showed that the microdialysis-CLC method was suitable to measure the drug behavior in lacrimal fluid after instillation. These findings provide significant information that can be used in the design and evaluation of ophthalmic formulation.
In a study to find ways to prevent the side effects of indomethacin (IMC), we previously reported that magnesium ion (Mg 2 ) can prevent the onset of IMC-induced gastric mucosa in adjuvant-induced arthritis (AA) rats, a model for rheumatoid arthritis (RA). In this study we investigated whether the co-administration of IMC and Mg 2 prevents the formation and aggravation of intestinal ulcerogenic lesions in AA rats. The single oral administration of an excessive dose of IMC (40 mg/kg) induces hemorrhagic lesions and nitric oxide (NO) production via inducible nitric oxide synthase (iNOS) in the jejunal and ileal mucosa of AA rats, and the extent of the lesions, as well as iNOS and NO levels in AA rats are higher than in normal rats. On the other hand, the co-administration of 200 mg/kg Mg 2 attenuates intestinal ulceration and the elevation in the iNOS and NO levels in AA rats. Further, hemorrhagic lesioning and enhanced iNOS and NO levels in AA rats also result from the repetitive oral administration of 3 mg/kg IMC (therapeutic dose) for 42 d (once a day), and these changes are also prevented by the co-administration of 200 mg/kg Mg 2 . In conclusion, the co-administration of Mg 2 suppresses the ulcerogenic response to IMC in the jejunal and ileal mucosa of AA rats, probably by preventing the elevation of iNOS and NO levels in the region. ; however, it is well known that the oral administration of these drugs leads to gastroenteropathy as a significant side effects, 2) and that RA patients taking NSAIDs are more susceptible to NSAIDs-induced intestinal ulcerogenic lesions than other patients or control subjects.2-4) Therefore, the development of NSAIDs that do not cause gastroenteropathy or other significant side effects is highly desired.It has been reported that a decrease in prostaglandins and excessive production of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are related to the formation and pathogenesis of intestinal ulceration induced by NSAIDs. [4][5][6][7][8][9][10][11] In addition, we previously reported that the co-administration of magnesium ion (Mg 2+ ) and NSAIDs (indomethacin (IMC) and loxoprofen) prevents the increase in iNOS and NO production in the gastric mucosa, resulting in the inhibition of the onset of NSAIDs-induced gastric lesions.12,13) Therefore, the co-administration of Mg 2+ may also suppress the onset of intestinal ulcerogenic lesions by NSAIDs, and lead to develop a method for administering NSAIDs that will not lead to gastroenteropathy.The changes in the biological characteristics of adjuvantinduced arthritis (AA) rats correspond to those that occur in human RA. 2,4,14,15) Moreover, AA rats have been reported to show gastric and small intestinal mucosal lesions induced by IMC, naproxen, and aspirin. 2,4) In addition, the gastric and small intestinal mucosal lesions in AA rats administered conventional NSAIDs are significantly aggravated as compared with normal rats.2,4) These findings suggest the AA rats may provide a useful model for studies on the suppression ...
Foreign matter sensation and blurred vision following instillation of ophthalmic suspension are often observed, and remaining of solid particle on cornea is related these side eŠects. In addition, low dispersion stability in the ophthalmic suspension aŠects the therapeutic eŠect. In this study, we have attempted to enhance the dissolution rate and stability of commercially available pirenoxine ophthalmic suspension (CA-pirenoxine eye drops), anti-cataract eye drops, by changes in particle size. Methylcellulose, zirconia beads (0.1 mm) and Micro Smash were used to mill the pirenoxine (bead mill method), and the distribution of particle size was changed to approximately 60 900 nm (nanodispersions) from 70 nm 3 mm (CA-pirenoxine eye drops). The dissolution rate of pirenoxine increased by the bead mill, and the dissolution rate constant in pirenoxine nanodispersions was 2.1-fold than that in CA-pirenoxine eye drops. Moreover, the dispersion stability in nanodispersions also signiˆcant higher in comparison with the CA-pirenoxine eye drops. The dispersion ratio in CA-pirenoxine eye drops and pirenoxine nanodispersions at 2 d after suspension was 48%, 99%, respectively. In conclusion, we showed that the dissolution rate and dispersion stability of CA-pirenoxine eye drops were enhanced by the bead mill method. Theseˆndings provide signiˆcant information that can be used in the design of ophthalmic suspension.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.